Chemoimmunomodulation of MDSCs as a novel strategy for cancer therapy.
Tumor-induced myeloid-derived suppressor cells (MDSCs) are a critical barrier to effective immunotherapy of cancer. We identified that Docetaxel and a natural compound, Icariin, can target MDSCs with preferential apoptosis of M2 cells and polarization of the surviving cells towards M1 cells. Such strategic targeting of MDSCs restored T cell function accompanied by tumor retardation in vivo.
H. Lee Moffitt Cancer Center; Department of Immunology; Tampa, FL USA.
Julie
J
Djeu
Sheng
S
Wei